Venous Blood Collection Devices Market Size

Venous Blood Collection Devices Market Overview

The venous blood collection devices market is anticipated to reach USD 6.00 Billion by 2030 at 6.40% CAGR during the forecast period 2022-2030, says market research future (MRFR). Concerns about infectious diseases spreading through donated blood have increased blood and products sales. In general, both hospital and independent laboratories evaluate each test to determine whether to recommend discussions with laboratory hematologists for tests with a higher risk profile or not to offer tests that could not be conducted safely. However, during the forecast period, hazards associated with product contamination, considerable pricing pressure, and lower quality devices from unknown manufacturers are expected to hinder the worldwide venous blood collection devices market.

However, rising testing volumes, increasing caution, and the requirement for frequent health and body examinations will ensure market growth in the future. Furthermore, as people become more aware of the benefits of venous blood collection devices over their alternatives, the market for them is growing. Furthermore, the rise in chronic and infectious illness instances and an aging population that is more susceptible to these diseases has increased demand for venous blood collection equipment, driving the venous blood collection market's growth.Segmentation

The global venous blood collection devices market has been segmented on the basis of type, material, application, and end-user.

On the basis of type, the market is segmented into blood collection tubes, needles, vacuum blood collection system, microfluidic system, micro-container tubes, micro-hematocrit tubes, warming devices, and others. Other devices include venous cannula and blood bags. The blood collection tube is further sub-segmented into plasma separation tube, heparin tube, serum separating tube, EDTA tube, and others.

On the basis of material, the global venous blood collection devices market is segmented into plastic, glass, stainless steel, ceramic, and others.

On the basis of application, the venous blood collection market is segmented into vein blood gas sampling and intraoperative blood salvage. Vein blood gas sampling is further sub-segmented into the diagnosis of disease and acid-base status monitoring.

On the basis of end-user, the global venous blood collection devices market is segmented into hospitals and clinics, the point of care, blood donation centers, diagnostic centers, and others.

Regional Analysis  

The global venous blood collection devices market consists of four regions, namely, the Americas, Europe, Asia Pacific, and the Middle East and Africa.

The Americas region accounted for the largest market share of the global venous blood collection devices market owing to the fastest uptake of new surgical techniques and instruments in the North American region, thus driving the market. Moreover, the extensive use of screening techniques and high expenditure on health care in the U.S. is driving the market growth. The greater awareness in developed regions along with the good reimbursement scenario drive the Americas market.

The European region accounted for the second largest market owing to high income and healthcare penetration. The Asia Pacific region is expected to increase during the forecast period owing to the growing healthcare sector in leading regions such as China and India. The major driving factors of the venous blood collection devices market are the increasing geriatric population, growth in demand for safe blood assortment technologies, increase in demand for improved blood sampling techniques, and increase in preference towards disposable products for the laboratory.

The Middle Eastern region is expected to grow at a steady pace owing to factors such as rising R&D activities in the healthcare sector and extensive development of the healthcare infrastructure. Gulf nations such as the U.A.E. and Saudi Arabia are projected to drive the Middle Eastern and African market. The government has undertaken various awareness programs for safe blood transfusion procedures which are further improving the health conditions in underdeveloped regions of Africa.

Key Players

• Becton


• Dickinson and Company (U.S)


• Bio-Rad Laboratories, Inc. (U.S)


• NIPRO Medical Corporation (Japan)


• Qiagen NV (Netherlands)


• F. Hoffmann-La Roche Ltd (Switzerland)


• Greiner Bio One International GmbH (Greiner Group) (Austria)


• Terumo Medical Corporation (Japan)


• Sekisui Chemical Co., Ltd. (Japan)


• Sarstedt AG & Co (U.S.)


• F.L. Medical (Italy)


• Narang Medical (India)


• Soya Green Tec Co., Ltd. (South Korea)


• Biosigma (U.S.)


• Vital Diagnostice (ELITech Group) (U.S.)


• Improve Medical Technology Co. Ltd. (U.S.)


• Hongyu Medical (China)


• SanLI (Myanmar.)


• KHB (U.S.)


• Zhejiang Gongdong Medical Technology Co., Ltd. (China)


• CDRICH (China)


• Radiometer Medical ApS (Danaher Corporation/ Danrad ApS) (Denmark)


• Medtronic Plc (U.S.)


• Fisher Scientific (Thermo Fisher Scientific Inc.) (U.S.)


• Kabe Labortechnik GmbH (Germany)


• Allegro Medical Supplies Inc. (Scrip Products Corporation) (U.S.), and others.

• 
  Mar 2022 The first patient received in a U.S. early feasibility report of Vivasure Medical's next-generation PerQseal+ device, according to the company. PerQseal+ will be tested in percutaneous transcatheter aortic valve replacement operations by Vivasure, a company based in Ireland. PerQseal Blue is another product that the company is working on. PerQseal Blue is a suture-less and fully absorbable large-bore venous artery closure device developed by the firm after percutaneous cardiovascular procedures such as transcatheter mitral valve replacement or repair and transcatheter tricuspid valve repair or replacement.


• 
  Feb 2022 Roche's Foundation Medicine has been granted regulatory permissions for an assay that detects circulatory tumor DNA (ctDNA) in plasma, making it one of the most recent FDA breakthrough designations. After curative therapy, the FDA has given the test breakthrough status for detecting molecular residual disease (MRD) in initial cancer patients. Because some medicines remove tumors but leave residual illness, a patient's MRD status can assist in determining whether additional treatment is required and the risk of return.

Intended Audience

• Venous Blood Collection Devices Manufacturers


• Venous Blood Collection Devices Suppliers


• Venous Blood Collection Tube Manufacturers


• Venous Blood Collection Tube Suppliers


• Biotechnology Companies


• Hospitals and Diagnostic Centers


• Academic Research Institutes


• Government Institutes


• Medical Research Laboratories